A recent study by NYU Langone Health found that popular weight-loss drugs might increase the risk of hair loss in men predisposed to male-pattern baldness. The research suggests a connection between GLP-1 medications, such as Ozempic, Wegovy, and Zepbound, and androgenetic alopecia. The findings, published in the Journal of Investigative Dermatology, supply the first genetic evidence linking GLP-1 activity to this common form of hair loss in men.

Possible Explanations for the Link

General Practitioner Dr. Ahmed El Muntasar, who was not involved in the study, discussed potential reasons for this link. He explained that rapid weight loss and nutritional deficiencies might cause temporary hair shedding. In those genetically predisposed to male-pattern hair loss, GLP-1 receptor activity could contribute to the underlying process.

According to the Centers for Disease Control and Prevention (CDC), over 25% of adults with diagnosed diabetes utilized GLP-1 injectables in 2024, with similar usage rates among men and women.

First Genetic Evidence of the Link

Study senior investigator Lynn Petukhova, an assistant professor at the NYU Grossman School of Medicine, highlighted that this study provides the first genetic link between GLP-1 use and increased risk of male-pattern hair loss. Researchers found a 7% increased risk of hair loss and focused on the GLP1R gene, which naturally boosts GLP-1 receptor protein levels in the body.

The team compared genetic markers associated with higher GLP-1 activity with those linked to androgenetic alopecia, a genetic condition causing hair loss along the top and front of the scalp. Male-pattern baldness was selected due to its well-understood genetic causes, facilitating investigation into potential causal relationships.

Beyond Rapid Weight Loss

GLP-1 medication users frequently report hair thinning. Until now, rapid weight loss has been the primary explanation, disrupting normal hair growth temporarily. Many regain hair once weight stabilizes. The new study, however, indicates a possible biological connection beyond mere weight loss.

The researchers adjusted their analysis for factors affecting hair growth, such as hypertension, insulin resistance, and lower testosterone levels. The 7% increased risk persisted after these adjustments.

The study analyzed genetic data from more than 31,000 men and women in the eQTLGen database, alongside over 205,000 men in a separate genetics database. Most participants were white. Overlapping genetic signals linked to both GLP-1 activity and androgenetic alopecia reinforce the case for a biological link.

Implications for Patients

Petukhova mentioned that if future studies confirm these findings, men and potentially women might undergo screening to assess hair loss risk before receiving GLP-1 medications.

El Muntasar advised against panic or discontinuing treatment based on a modest 7% increase. He explained that the research used genetic data and Mendelian randomization, offering a biological signal rather than definitive proof that weight-loss injections will cause baldness.

Petukhova suggested that the findings could lead to preventative strategies, like prescribing medications that reduce hair loss alongside GLP-1 therapies. Further studies are necessary to understand how GLP-1 pathways affect hair follicles and whether similar genetic relationships exist in women.

With around half of white American men over 50 affected by androgenetic alopecia, understanding potential side effects of GLP-1 drugs is crucial. As GLP-1 usage rises, identifying those at risk should become a priority.